Havard Robert, Stephens Deborah M
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, Salt Lake City, UT, 84112, USA.
Curr Hematol Malig Rep. 2018 Dec;13(6):534-542. doi: 10.1007/s11899-018-0482-6.
This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma.
The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1, JULIET, and TRANSCEND NHL-001 trials. Anti-CD19 CAR-T therapy is an exciting new therapy now approved and available to patients with relapsed/refractory diffuse large B cell lymphoma. Secondary to the increasing success and availability of these products, caregivers should expect to become familiar with the indications, toxicity, and limitations of these treatment options and when patients should be considered for referral.
本文将综述抗CD19嵌合抗原受体T细胞（CAR-T）疗法在复发/难治性弥漫性大B细胞淋巴瘤中的应用。
将讨论临床结果、安全性分析及其他相关考量因素，重点关注关于ZUMA-1、JULIET和TRANSCEND NHL-001试验的最新发表数据。抗CD19 CAR-T疗法是一种令人振奋的新型疗法，现已获批用于复发/难治性弥漫性大B细胞淋巴瘤患者。由于这些产品的成功率不断提高且可及性增强，护理人员应熟悉这些治疗方案的适应症、毒性和局限性，以及何时应考虑将患者转诊。
